SUMMARY.
Of the somatomedins so far measured, the selective quantitation of insulin-like growth factor I (IGF-I) appears to have the greatest potential in clinical diagnosis. There have been two approaches to the development of immunoassay systems. One type uses antibodies raised against synthetic fragments of IGF-I which exhibit cross-reactivity with the whole hormone. Such assay systems may be adequate for measuring normal adult plasma IGF-I levels, but the potential for the higher sensitivity required for detecting sub-normal plasma levels in young children is apparent only in methods using antibodies raised against the complete hormone.
IGF-I in plasma exists as part of a high molecular weight complex in which it is bound to carrier proteins. The binding proteins may interfere with plasma IGF-I measurements by radioligand assays. Direct analysis of untreated plasma samples is claimed to be possible using disequilibrium assay conditions but in order to maximise assay sensitivity it is necessary to employ an initial extraction stage in order to eliminate binding·protein interference.
Whether the measurement of plasma IGF-I can or should be used in addition to, or as a replacement for, plasma growth hormone (GH) measurement in the clinical assessment of growth disorders remains a controversial issue. Available evidence indicates that a single, random plasma IGF-I level provides an accurate reflection of GH secretion. Adequate discrimination between the elevated levels in acromegaly and normal reference values has been demonstrated. However, in the investigation of growth-retarded children available radioimmunoassay (RIA) methods have proved only partially successful because of the age-related nature of normal plasma IGF-I concentrations. Existing assays appear capable of identifying sub-normal plasma levels after the age of approximately 4 years. In younger subjects an improvement in assay sensitivity is required in order to establish with greater accuracy the relevant normal ranges.
Improvements in the identification of the particular lesion responsible for retarded growth in a child can be achieved by measurement of both plasma GH and IGF-I concentrations. The predictive value of the acute plasma IGF-I response to single-dose GH therapy may identify patients who will respond to long-term GH therapy. Better, more informed decisions on subsequent treatment may therefore be made.
Apart from GH control, several other factors influence circulating IGF-I levels. Nutritional status can be assessed through reference to IGF-I analysis, overall catabolic or anabolic processes being associated with decreasing or increasing plasma IGF-I levels respectively.
In 1957 the first report by Salmon sulphation factor was shown subsequently to promote other anabolic processes. About this time Froesch/ and his research group were extracting from serum a preparation possessing insulin-like activity (as defined by its ability to stimulate glucose uptake by diaphragm or adipose tissue) which could not, unlike insulin itself, be neutralised by anti-insulin antibodies.
The non-suppressible insulin-like activity (NSILA) was further purified by Rinderknecht and Humber' who identified two pure polypeptides which were designated IGF-I and IGF-II. 4, 5 Approximately 50% of the amino acid sequences of each of the IGF's were shown to be homologous with proinsulin. Threedimensional models have been constructed" which clearly demonstrated the close structural similarities which would enable the IGF's to interact with insulin receptors, albeit weakly. 7, 8 In 1972, in an attempt to rationalise terminology, the term somatomedin was used by Daughaday et al." to describe sulphation factor. It was proposed that substances which are growth-hormone-dependent, have insulin-like actions on extra-skeletal tissues and stimulate sulphate incorporation into cartilage qualify as somatomedins. Several groupsW-12 working independently produced other preparations from serum with growth-promoting properties. In 1974 van Wyk et al. 13 described the purification of a basic peptide which they termed somatomedin-C (Sm-C).
All the available structural and immunochemical evidence supports the conclusion that IGF-I and Sm-C are identical." Recently, attention has concentrated on the use of IGF-I in clinical studies. Several studies using RIA's for IGF-I have provided information on the physiological significance of circulating levels of the hormone and on the potential clinical applications and interpretation of such measurement.
INSULIN-LIKE GROWTH FACTOR I
IGF-I is a basic peptide of 70 amino acids and a molecular weight of 7649. 13 The purification procedure used by Svoboda et al. 15 was similar to that used for other IGF preparations with the final isolation of the basic peptide by isoelectric focusing. From a starting material of 1200 Iitres of plasma approximately 250 \Lg of pure IGF-I resulted.
Circulating IGF-I is mainly of liver origin and its synthesis is, by definition, under GH control. Unlike GH, however, plasma concentrations of IGF-I are not subject to diurnal variation or the acute influences of stress, sleep, exercise or changes in circulating levels of nutrients.l" Part of the clinical assessment of GH status involves multiple blood sampling of patients being subjected to dynamic stimulation or suppression tests. Early indications suggest that random IGF-I measurements may obviate the necessity for such procedures.
Insulin-like growth factors are unique, as a group of polypeptide hormones, in that they circulate bound to high molecular weight carrier proteins. The relatively long half-life of IGF-I in serum, estimated at between 2 and 4 hours, 16 may be attributable to the formation of these complexes. It appears probable that the binding of somatomedins to carrier proteins accounts for their relatively high serum concentrations compared to those encountered for other peptide hormones. Two binding proteins have been isolated and most of the circulating IGF-I is attached to the one with a molecular weight of 150000 daltons.!" The smaller (50 000 dalton) carrier protein, although present in smaller amounts, binds IGF-I more rapidly. The hormone then shifts to the larger carrier. 18 The synthesis of carrier proteins is also under GH control.'? More than 99% of the somatomedins circulate in bound form and it has been suggested that the insulin-like effects are thereby neutralised.j" Since at least 90% of the total insulin-like activity in serum can be attributed to growth factors, the potential hypoglycaemic effects are regulated by the sequestration of growth factors by carrier proteins. Through these mechanisms the somatomedins exert their growth-promoting effects without undue lowering of blood glucose levels.
ASSAY METHODS
The evolution of IGF-I assay methodology has followed a pattern similar to that observed for many other hormones. Beginning with technically demanding bioassays there followed a period of radioreceptor assay systems when radio-iodination technology became available. (For a detailed review of bioassay and receptor assay methodologies consult reference 21).
The availability of purified hormone in sufficient quantity permitted the development of immunological assay systems through the production of antibodies. Only a few research groups have, however, been successful in producing sufficient quantities of intact hormone. No single tissue stores IGF-I, serum being the major source apart from biosynthetic material recently produced by genetic engineering.
As an alternative approach to tedious purification procedures, antibodies have been induced in animals immunised with synthetic fragments of the hormone. The resultant assays rely on the harvested antibodies exhibiting cross-reaction with the intact hormone in order that a viable system for measuring plasma IGF-I concentrations may be developed. Inevitably, such systems, whilst displaying a high affinity for extremely small amounts of specific antigen typical of an RIA, are capable only of much reduced affinity for the whole hormone. Normal adult plasma levels of IGF-I are in the 100-200 ng/ml range and these assays may still be of adequate sensitivity to discriminate the grossly elevated levels observed in acromegaly. However, in the application of such assays to measurement of the low IGF-I levels encountered in assessing GH deficiency (GHD) and the response to GH therapy, only those utilising antibodies to IGF-I itself appear ade~uately sensitive. A report by Hintz et at. 2 is a compilation of some published methods and their properties in terms of detection limits.
Antibodies raised against IGF-I or Sm-C have permitted the establishment of RIAs of greater specificity than any of the bioassay or radioreceptor assay methods described previously. Whilst IGF-I and Sm-C display equal cross-reactivity with such antibodies, other somatomedins or growth factors have shown negligible interaction. 14 Although the carrier proteins maintain serum IGF-I at relatively constant levels, they also represent a major obstacle when attempting to assay the hormone in untreated samples. Some early methods employed direct hormone measurement" but subsequently it was recognised that variations in sample handling and/or assay conditions could produce different results. 24 . 25 Such variations were attributed to dissociation of hormone from carrier, thus rendering it more available for interaction with assay antibody. In addition, the presence of another binding agent (carrier protein) in the assay system distorted tracer equilibrium with the assay antibody. A simple extraction method/" has been described and produces quantitative recovery of IGF, thereby enhancing discrimination between IGF-I levels found in hypopituitary and normal subjects.
Methods and materials
Studies in this laboratory have been based on clinical data accumulated using an IGF-I RIA system described and developed by Baxter, Brown and Turtle.r" The method employs antibodies raised in rabbits by immunisation with purified IGF-I conjugated to ovalbumen using glutaraldehyde. Iodinated hormone is prepared by conventional chloramine T oxidation followed by a two-stage purification proce-
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dure. The first stage involves the removal of non-hormone iodination reagents by simple gel filtration. Further purification of the iodinated hormone by hydrophobic interaction chromatography results in the isolation of pure tracer comparable in immunoreactivity to an affinity purified preparation. 28 Plasma or serum samples are extracted with acid-ethanol" and serial dilutions of the neutralised ethanolic supernatant incubated with antiserum Tr9 and tracer. Sufficient dilutions are produced so that measurements may be made within the assay working range. Fig. 1 shows assay standard curve using two different antisera. The assay on which the clinical data to be presented later is based uses antiserum Tr9,27 has a detection limit (sensitivity) of 0·04 U/mL and working range of 0·05-0·50 U/mL. Although antiserum AS6 (NIADDK) yielded a lower detection limit (0,01 U/mL) , restricted supplies did not permit its further use in specimen analysis. A serum pool from adult volunteers is used as the standard reference preparation. Standardisation of individual assay systems has been a major problem. The lack of adequate quantities of purified hormone prohibits its use as a primary standard preparation and most assayists have resorted to the use of pooled serum from normal individuals to which is assigned an arbitrary value of 1 unit of IGF-I per mL. As a result, direct comparisons between results from different laboratories may be of doubtful significance. Specificity studies with the two antisera (Tr9 and AS6) have already been described by Baxter et al., 27 together with data on the rationalisation of the assay procedure and quality assurance parameters.
Results and discussion
AGE DEPENDENCY OF PLASMA IGF-] CONCENTRATIONS Figure 2 shows the results from the analyses of 476 samples taken from children being investigated for short stature. The samples were random collections or basal specimens from GH provocation tests (e.g. stimulation by insulin-induced hypoglycaemia, clonidine, exercise or Bovril). The results are grouped according to age and sex.
The pattern of plasma concentration observed is similar to that published by othersf': 29--33 and reveals low-sometimes undetectable-levels in children within the 0-3 years age group, a peak at puberty, followed by a small decrease to adult values. Plasma IGF-I levels are generally higher in girls than in boys throughout childhood.
The interpretation of plasma IGF-I levels in children in the 0-3 age group must be made cautiously since currently the combination of the restricted availability of samples from normal healthy subjects and the lack of sensitivity of most assay systems renders identification of sub-normal IGF-I values difficult. Further development of sensitive assay systems, optimised to deal specifically with the analysis of specimens from the lower age group, may improve the diagnostic value of such measurements. The potential for such a development is already evident through the use of an antiserum of high avidity such as AS6 (Fig. 1) .
The lower limit of the reference range for 0-3 year olds is near the assay detection limit and is based on comparatively few measurements. The range, the width of which is a consequence of a few high results in this age group, must, therefore, be looked upon as no more than provisional at the present time. No concentrations of less than 0·1 U/mL have yet been found in the 0-3 age group but since this is a period of relatively rapid growth it might be expected that the plasma IGF levels would be much higher than at other ages. It may be concluded, therefore, that IGF-I deficiency in this age group is rare and that even the smallest concentrations are sufficient to maintain growth through stimulation at extra-sensitive receptors on target tissues.r"
Plasma IGF-I levels in healthy adult volunteers fall within a range of 0-4-2·0 U/mL. This range is maintained until the age of 40 years when it begins to fall. This change in adult normal range becomes relevant when assessing the biochemical status of elderly patients with acromegaly. Therefore, it is important to estab- Age Groups Iish comprehensive reference ranges throughout the complete age range and for both sexes. Figure 2 also shows 21 results classified as sub-normal during establishment of the reference ranges. The numbered results are from patients on whom further clinical information was obtained and the probable cause of the low IGF-I identified. These will be discussed in more detail in the relevant sections.
INVESTIGATION OF SHORT STATURE
Of the 21 cases (Fig. 2) identified as having abnormally low plasma IGF-I levels, 17 have been sub-classified according to their GH status ( Table 1 ). The other four cases in which the low plasma IGF-I levels were not directly associated with GH abnormalities will be discussed in a later section. In Group A three patients were shown to be GH deficient through a lack of response to insulin-induced hypoglycaemia. These patients received GH therapy. Subsequent measurement of IGF-I in two of them showed stimulation of IGF-I levels into the normal range. Group B contains five cases, .in all of whom an adequate GH response could be elicited using various stimuli (other than insulin stress) such as exercise, sleep, clonidine or Bovril. In view of the normal GH response, no further treatment of these patients was instituted. It is assumed, however, that this group did contain cases of biologically inactive GH production who might have benefited from GH therapy had it been given.
No cases of elevated basal GH levels in association with either sub-normal or elevated IGF-I levels were identified throughout the survey, indicating the relatively low incidence of these causes of short stature.
Group C comprised three cases in which GH responses to the stimuli used in Group B were equivocal. As with Group B, no follow-up investigation of these patients was initiated. Group D contained six cases in which low GH levels were obtained in random or post-Measurement of IGF-I 417 stimulation specimens. The stimulus was by other than insulin stress. In two of these cases radiotherapy to the head and neck had been given.
An examination of these cases is an attempt to demonstrate the use of IGF-I measurements in the investigation of short stature. Uncertainty has arisen in the clinical application and interpretation of pharmacological stimulation tests for GH response as knowledge about the control of GH secretion has advanced.P Lack of an adequate GH response to stimulation by hypoglycaemic stress can no longer be regarded as the definitive test in the diagnosis of GHD. Whilst such a diagnosis may be confirmed by a low plasma IGF-I concentration, the combination of low GH but normal IGF-I levels should encourage further investigation. Other classifications of growth retardation have arisen as a result of the availability of IGF-I measurements. Low IGF-I levels may be associated with apparently normal (or supra-normal) GH responses to pharmacological stimuli.t" Since RIA of GH is a measurement of immunological rather than biological activity, alternative methods of assessing GH status have been devised. One of the first methods to be employed involved the use of a radioreceptor assay (RRA) in combination with RIA to indicate a ratio of biologicaV immunological GH activity. A low RRNRIA GH ratio combined with a low basal IGF-I level indicates the production of a biologically inactive endogenous GH. 37 Other sub-groups display normal plasma GH levels (by RRA and RIA) and low basal IGF-I levels which do not respond to GH therapy.P: 39 The occurrence of high basal GH levels in association with low plasma IGF-I levels and clinical unresponsiveness to exogenous GH was first described by Laron et at.40 This type of dwarfism is thought to be the result of a receptor defect in the somatomedin-producing cells. In another type of dwarfism not only is 8, 9, 11, 13, 14, 17 10, 20 19 21
Comments GHD subsequently treated with GH Normal GH response to stimulation Equivocal GH response Low G H response Post-treatment plasma IGF-I increase Later treated with thyroxine the basal plasma GH level raised but so also is IGF-I, indicating a peripheral resistance at specific somatomedin receptor sites. In these circumstances interaction of the elevated IGF-I with insulin-binding receptors can lead to hypoglycaemia as a manifestation of its insulinlike activity. 41 
TREATMENT OF SHORT STATURE

Growth hormone
A further manifestation of the GH-dependence of IGF-I production is provided by the observation that low plasma IGF-I levels in children with GHD generally rise following successful treatment with GH. Figure 3 shows the acute responses following doses of GH administered either intramuscularly (four units) or subcutaneously (1,7 units) to a small group of GH-deficient children of various ages. In all except one case plasma IGF-I levels increased after GH administration.
Long-term treatment (maximum 190 days, minimum 124 days) of the' same patients did not increase plasma IGF-I levels much above those produced by the acute stimulus (data not shown). In two patients the withdrawal of treatment resulted in a fall in plasma IGF-I levels to pre-treatment basal values.
Other, larger studies have attempted to correlate acute and chronic IGF~I responses to GH therapy and to evaluate the potential of basal and stimulated plasma IGF-I levels in the prediction of subsequent growth rates. Rosenfeld, Kemp and Hintz'" have shown that the acute response may predict long-term plasma IGF-I levels and that the levels remain constant irrespective of the duration of therapy or variation in growth rate. Their study also indicated that the IGF-I response is age dependent and neither basal nor GH-stimulated plasma IGF-I levels could be correlated with the growth response. Russo and Moore.v' however, reported that the response to acute GH administration did correlate with the growth rate observed during long-term GH therapy and that the route and timing of GH administration influences the initial plasma GH levels and consequently IGF-I production.
Copeland, Underwood and van Wyk 44 postulate that the relatively slow response of plasma IGF-I to acute GH stimulation implies that it is not stored for instant release but is synthesised de novo. A graded IGF-I response may, however, be elicited by increments in GH dose and the magnitude of the response is influenced by previous therapy; a greater IGF-I response being observed following a second and subsequent doses of GH.
In this area of growth factor research longterm studies are required with painstaking documentation of analytical data from plasma GH and IGF-I measurements made during different treatment regimes and their effect on growth rate. 
Grawtn hormone releasing factor (GRF)
With the availability of purified 45 and synthetic" GRF, several reports have described its use for differentiation between hypothalamic and prima~pituitary defects in GH secretion.f?" Some of these, in addition to reporting GH responses to GRF administration, also describe changes in plasma IGF-I levels during treatment. 4 9-52 As a result, it has been suggested that a single plasma IGF-I measurement may be a better discriminator of efficacy in GH-deficient patients than several plasma measurements taken over a period of time. 49 The increase in plasma IGF-I levels has also been recognised as more important than the rise in immunoreactive GH as an index of the likely response in linear growth:50
Treatment of a hypothalamic deficiency with GRF, rather than with GH, should preserve the feedback effects of IGF-I at the pituitary, producing a more physiological response.P'' In contrast to these positive reports, two others": 52 described no effect of GRF infu-Age \vecr s: i<ormal !iormal tGH . ." sions on plasma IGF-I levels. The use of GRF, nevertheless, has widened the opportunities for the treatment of GH deficiency.
INFLUENCE OF NUTRITION
During the screening of growth-retarded children in this laboratory, three of the 21 abnormally low plasma IGF-I levels were found to be associated with some form of intestinal malabsorption ( Fig. 2; Table 1 ). Two (Cases 10 and 20) were cases of cystic fibrosis and one case of Crohn's disease (Case 19). All three patients had normal plasma GH responses on stimulation. Following successful surgical treatment of the Crohn's disease a subsequent measurement of IGF-I showed an increase into the normal range. Such cases of malabsorption may be considered to be disorders of nutrition.
Malnourished children display normal or elevated plasma GH levels, low plasma IGF-I concentrations and inadequate growth. Restoration of adequate nutrition produces normalisation of plasma GH and IGF-I levels.
normal reference ranges. In 14 of these cases basal GH levels were elevated but suppressed by glucose. In 71 cases where basal plasma GH concentrations were observed to be elevated and/or non-suppressible, IGF-I levels were seen to be elevated in all but four patients. Further investigation of these four patients is required to establish an explanation for the apparently normal IGF-I, or elevated GH, levels. This data encourages the conclusion that a single, random plasma IGF-I measurement may prove to be a significant contribution to the diagnosis of acromegaly without the need to subject patients to lengthy suppression tests.
Serum or plasma IGF-I levels have been reported to show better correlation not only with disease activity but also with the degree of improvement in response to therapy. 53, 54 However, other reports indicate that both GH and IGF-I measurements have a poor correlation with symptomatic improvement in treated acromegaly.P The apparent discrepancies between the various studies which attempt to correlate plasma IGF-I levels with either severity of the illness and or efficacy of treatment may be attributable to differences in assay methodology. In particular, some reports involve direct analysis of samples with the consequent interference of binding proteins, the levels of which may show gross variations in the acromegalic state. Further studies on the diagnosis and long-term treatment of the disease with concurrent measurement of extracted IGF-I levels are required to establish a better understanding and interpretation of hormone values.
... 
IGF-I LEVELS IN ACROMEGALY
Current practice involves the measurement of plasma GH levels as part of the biochemical investigation of patients with clinical signs of acromegaly. "Random basal levels are often raised and fail to suppress following a glucose load. Although non-suppressible plasma GH concentrations are often diagnostic, the observed levels may not correlate with total GH output or the severity of the illness. In this laboratory plasma IGF-I measurements have been made on groups of patients in whom acromegaly was suspected or had already been diagnosed. Figure 4 shows the results obtained. Patients are grouped by age and basal GH level. Patients with elevated basal GH levels which proved to be suppressible by a glucose load were classified as having normal GH levels.
In all 43 cases where plasma GH concentrations were shown to be normal or suppressible plasma IGF-I levels were seen to be within Similar hormonal and growth patterns have been observed in anorexia nervosa." Obese children may have poor plasma GH responses to hypo glycaemia and other stimuli but have normal plasma IGF-I levels and exhibit normal or accelerated growth. 57 The influence of adequate nutrition of IGF-I is further illustrated in a study which examined the plasma IGF-I response to GH treatment in the fed and fasted states." Low plasma IGF-I levels were observed following a 3-day fast, both in GH-deficient patients undergoing GH treatment and in normal volunteers. The low IGF-I levels were not increased by GH treatment indicating the induction of a resistance to GH during starvation. Recent data suggests that the relative resistance may be correlated with decreases in plasma levels of insulin and triiodothyronine. 59 The normalisation of plasma IGF-I levels in fasted volunteers requires the combined stimulus of both protein and energy intake.?" If total caloric intake is low, plasma IGF-I levels remain low and a direct correlation between increases in protein content and plasma IGF-I levels has been demonstrated. It has been suggested that the measurement of plasma IGF-I may be a useful indicator of nitrogen balance and that a low plasma IGF-I in the presence of a normal plasma GH can often be attributable to nutritional insufficiency.
Plasma IGF-I activity can fall rapidly to very low levels following severe injury."! The reason for this decrease is not known but the levels are low during the early part of the catabolic phase and begin to rise in the later stages. Normal GH control of IGF-I is lost during this post-injury period and in this situation the influence of insulin on IGF-I control may be greater than that of GH. The overall picture, post-trauma, is one of depressed plasma IGF-I levels in association with high plasma levels of stress hormones (GH, cortisol, catecholamines), low plasma insulin levels and a general catabolic response. Following recovery into the anabolic phase, the increase in plasma levels of insulin and IGF-I show a significant positive correlation.?!
INFLUENCE OF OTHER HORMONES
Insulin (diabetesthypoglycaemia)
It is well known that growth retardation occurs in patients with juvenile diabetes mellitus (type I). Plasma IGF-I levels are often sub-normal until adequate diabetic control is obtained, when levels are seen to increase with concomitant acceleration in growth rate. 62 Even when adequate metabolic control with insulin therapy and dietary regulation is obtained, some children may still exhibit growth disturbance. As well as the observed lack of growth, plasma GH levels are elevated and plasma IGF-I levels sub-normal, in a situation analagous to Laron dwarfism and acute malnutrition.
In adults with diabetes plasma IGF-I levels have been reported to be increased, decreased or to be unchanged and, moreover, they are said to be variously affected or unaffected by treatment. A survey of these conflicting reports concluded'" that IGF-I levels are higher in type I than in type II diabetes. High plasma IGF-I levels in diabetics of either type appear to be predictive of subsequent development of rapidly accelerating retinopathy. 64 The measurement of plasma IGF-I levels in newlydiagnosed diabetics may therefore be useful in determining the type of treatment required.
In this laboratory data from patients under investigation for hypoglycaemia (blood glucose below 2·2 mmol/L) are shown in Fig. 5 . In all except two cases the hypoglycaemia was associated with hyperinsulinaernia. In only one case was an elevated plasma IGF-I level observed. This case was a 14-year-old girl in whom hypoglycaemia was associated with hyperinsulin- aemia and it could not, therefore, be directly attributed to the insulin-like effect of IGF-I. In view of the age of the patient, it is probable that the hyperinsulinaemia had caused excessive stimulation of IGF production.
The pathogenesis of non-islet tumourassociated hypoglycaemia has attracted much speculation. One theory is that insulin-like substances are involved as causative factors but reports are contradictory. One has described subnormal plasma IGF-I but elevated IGF-II levels;65 other studies have reported decreased plasma IGF-Il and marginally subnormal IGF-I levels.I" The discrepant evidence could be a consequence of the various assay methodologies involved.
Evidence of elevated plasma IGF has been sought to explain the hypoglycaemia associated with hepatomas. However, in many cases, plasma IGF levels are sub-normal, possibly due to decreased IGF production consequent upon hepatic dysfunction such as may be seen in cirrhosis or chronic hepatitis.f"
Androgens/oestrogens
In view of the observed growth spurt in children during puberty the effects of treatment with androgens'" or oestrogens?" on plasma IGF-I levels have been examined. Available data do not suggest any direct stimulation of IGF-I production by sex hormones but rather that the increase in plasma IGF-I during puberty is a consequence of the increase in GH secretion acting synergistically with the sex hormones. An adequate plasma IGF-I level may be one factor in normal development during puberty and its measurement could provide information in the isolation of any defect.
Placental lactogen/prolactin HPL may play a role in maintaining foetal growth, and during pregnancy maternal plasma levels of IGF-I are raised. 2Y Our results confirm this observation (Fig. 5) .
Hyperprolactinaemia in the later stages of pregnancy may also account in part for the elevated plasma IGF-I levels observed in pregnant women. Prolactin has also been shown to be an effective stimulator of plasma IGF-I levels in GHD patients but not in normal subjects. It is postulated that the presence of a prolactinoma in GHD patients can maintain normal IGF-I output.I" In our studies patients with normal GH output and hyperprolactinaemia on plasma IGF-I levels were found to be within normal limits (Fig.5 )
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Thyroid hormones Although some studies have shown reduced plasma levels of IGF-I in adults and children with hypothyroidism," I no significant changes in plasma IGF-I levels can be observed in data from untreated hypothyroid adults in this laboratory (Fig. 5) . Only one child has presented with hypothyroidism during the period of this study and the pre-treatment plasma IGF-I level was sub-normal (Case 21; Fig. 2) . Following a period of thyroxine therapy the TSH level fell to within normal limits and the plasma IGF-I concentration increased to 0·55 U/mL. Figure 5 also shows apparently normal plasma IGF-I levels in patients with thyrotoxicosis.
